Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 16/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23635896 | 0.89 | HSD17B10 (0.57) | STING1HSD17B10MKNK2MKNK1IKBKB | |
| SCHEMBL23630822 | 0.83 | STING1 (1.00) | STING1IKBKB | |
| SCHEMBL23630831 | 0.78 | STING1 (0.51) | STING1HSD17B10IKBKB | |
| SCHEMBL30765071 | 0.77 | STING1 (0.86) | STING1IKBKB | |
| SCHEMBL23111973 | 0.77 | STING1 (0.86) | STING1IKBKB | |
| SCHEMBL23630804 | 0.76 | STING1 (1.00) | STING1 | |
| SCHEMBL23630832 | 0.76 | STING1 (0.84) | STING1 | |
| SCHEMBL23635878 | 0.74 | STING1 (1.00) | STING1 | |
| SCHEMBL23635912 | 0.74 | STING1 (0.82) | STING1HSD17B10 | |
| SCHEMBL23635894 | 0.73 | STING1 (0.72) | STING1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD. (AU) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | STING1 1/4885HSD17B10 4085/4885MKNK2 3777/4885 |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | STING1 1/4885HSD17B10 4151/4885MKNK2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.